Press Releases

A team at Roswell Park Comprehensive Cancer Center has uncovered a link between survival and the number of tumor-infiltrating lymphocytes (TILs) in the tumors of breast cancer patients. Kazuaki Takabe, MD, PhD, FACS, Clinical Chief of Breast Surgery, Breast Program Leader and Breast Disease Site Leader at Roswell Park, served as principal investigator of the new study published in Annals of Surgery. Rongrong Wu, MD, and Masanori Oshi, MD, of the Department of Surgical Oncology at Roswell Park were first authors of the study, which was completed in collaboration with colleagues in Japan.

A novel study led by medical oncologists Deepak Vadehra, DO, and Sarbajit Mukherjee, MD, MS, to be presented in a podium presentation at the ASCO 2023 Annual Meeting is shedding light on factors that may affect treatment response in younger people with CRC. The information could guide the development of new treatments for younger patients, who typically have poorer outcomes.

Research has shown that the immune system doesn’t function properly in patients with multiple myeloma, a blood cancer that occurs when plasma cells — a type of white blood cell — multiply out of control. But a clinical trial led by Jens Hillengass, MD, PhD, Chief of Myeloma at Roswell Park Comprehensive Cancer Center, shows that exercise may have the power to strengthen the immune system in those patients, providing a nonpharmaceutical method of helping control the disease.

An observational cohort study out of Roswell Park Comprehensive Cancer Center demonstrates that race and ethnicity affect a woman’s 21-gene recurrence score, a tool used to determine risk of recurrence and distant metastasis in patients with early-stage, hormone-receptor-positive breast cancer. Based on the expression of 21 cancer-related genes detected in pre-treatment tumor specimens, recurrence score is used routinely in clinical care to identify patients who might benefit from chemotherapy as part of their treatment plan. Scores range from 0-100, with a score of 26 or higher indicating greater risk of recurrence and poorer overall survival.

Oncologists, epidemiologists and basic, translational and clinical researchers from Roswell Park have been invited to present their own research surrounding cancer management, ongoing clinical trials and more at the annual meeting of the American Society of Clinical Research (ASCO) in Chicago, Illinois, June 2 to 6.

Every year, more than 30,000 people contact the New York State Smokers’ Quitline for help in ending their dependence on commercial tobacco products. That lifeline will remain in place, thanks to the New York State Health Department’s renewal of its contract with Roswell Park Comprehensive Cancer Center, home of the Quitline since it began 23 years ago. Awarded on a competitive basis, the $20 million contract ensures funding for the program for the next five years.

Nationally prominent attorney Leecia Eve, Esq., has been named Interim Chair of the Roswell Park Comprehensive Cancer Center Board of Directors. A Buffalo native, she was named to the post by New York Governor Kathy Hochul, becoming the first woman and the first person of color to serve as Board Chair.

High-risk breast cancer patients who most closely followed cancer-prevention guidelines published by the American Institute for Cancer Research (AICR) and American Cancer Society (ACS) before, during and after chemotherapy experienced a 37% reduced risk of disease recurrence and a 58% reduced risk of death, according to a study led by Roswell Park Comprehensive Cancer Center. Researchers hope the information can be used to educate patients about ways they might improve their own outcomes even after diagnosis.

Evidence-based practice changes led by nurses from Roswell Park Comprehensive Cancer Center will be highlighted – and a longtime Roswell Park nurse recognized – at the 48th annual Oncology Nursing Society (ONS) Congress April 26-30, 2023, in San Antonio, Texas.